3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus et al. · Annals of Oncology · 2016
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years and a 5-year survival of only ∼25% [2–4]. Some more recent series seem to indicate an improvement in median overall survival [5, 6].
Cited by 2,033 works. doi:10.1093/annonc/mdw544 Open-access PDF
Authors
- Fátima Cardoso
- A. Costa
- Elżbieta Senkus
- Matti Aapro
- Fabrice André
- Carlos H. Barrios
- Jonas C. S. Bergh
- G.S. Bhattacharyya
- Laura Biganzoli
- Maria João Cardoso
- LA Carey
- D. Corneliussen-James
- Giuseppe Curigliano
- Veronique C Dieras
- N. El Saghir
- Alexandru E. Eniu
- Lesley J. Fallowfield
- Doris Fenech
- Prudence A. Francis
- Karen A. Gelmon
References
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- Associations Between End-of-Life Discussions, Patient Mental Health, Medical Care Near Death, and Caregiver Bereavement Adjustment
- Relationship Between Cancer Patients' Predictions of Prognosis and Their Treatment Preferences
- Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- Palbociclib and Letrozole in Advanced Breast Cancer
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer